The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy

Ranjan K. Mohapatra1 | Lucia Pintilie2 | Venkataramana Kandi3 | Ashish K. Sarangi4 | Debadutta Das5 | Raghaba Sahu6 | Lina Perekhoda7

Abstract
COVID-19 is highly contagious pathogenic viral infection initiated from Wuhan seafood wholesale market of China on December 2019 and spread rapidly around the whole world due to onward transmission. This recent outbreak of novel coronavirus (CoV) was believed to be originated from bats and causing respiratory infections such as common cold, dry cough, fever, headache, dyspnea, pneumonia, and finally Severe Acute Respiratory Syndrome (SARS) in humans. For this widespread zoonotic virus, human-to-human transmission has resulted in nearly 83 lakh cases in 213 countries and territories with 4,50,686 deaths as on 19 June 2020. This review presents a report on the origin, transmission, symptoms, diagnosis, possible vaccines, animal models, and immunotherapy for this novel virus and will provide ample references for the researchers toward the ongoing development of therapeutic agents and vaccines and also preventing the spread of this disease.

KEYWORDS
COVID-19 pneumonia, diagnosis, entry mechanism, possible vaccines, animal models and immunotherapy, symptoms, transmission

1 INTRODUCTION
Coronavirus (CoV) is a positive single-stranded RNA virus that causes respiratory infections such as common cold, flu, rarely pneumonia, and finally Severe Acute Respiratory Syndrome (SARS) (Tyrrell & Bynoe, 1966). It belongs to Coronaviridae family in the Nidovirales order. The external surface creates crown-like spikes of 9–12 nm long (Wei...
et al., 2020) and hence, termed as coronavirus (Latin: corona means crown). The genome (nucleic material) size varies from 26 to 32 kbs in length (Shereen, Khan, Kazmi, Bashir, & Siddique, 2020). There are four subfamilies, namely alpha-, beta-, gamma-, and deltacoronaviruses, exist till date. The alpha- and betacoronaviruses are originated from mammals (bats), whereas gamma- and deltacoronaviruses are originated from birds and pigs. There are seven human coronaviruses identified till date (Table 1; Chan et al., 2020; Franquet, 2011; Hensell et al., 2008; Lee, 2020; Malainou & Herold, 2019). Among these seven subtypes, betacoronaviruses are causing severe diseases and fatalities, while alphacoronaviruses cause mildly symptomatic infections. As per the genomic analysis, SARS-CoV-2 is identical with bat CoV (96%) and pangolin CoV (86%–92%), so bats could be the possible primary reservoir (GISAID, 2020; Shereen et al., 2020; Zhou, Yang, et al., 2020). The major four structural genes encode the spike protein (S), nucleocapsid protein (N), membrane glycoprotein (M), and small membrane protein (SM) with an additional hemagglutinin esterase (HE) if present (HE is only present in some betacoronaviruses). The genome RNA is complexed with N protein to form a helical capsid structure and found within the viral membrane. Trimers of S protein give the virion a crown-like shape. In some cases, HE protein also forms smaller spikes (Figure 1).

SARS-CoV-2 is a new strain of CoV for humans making the pandemic coronavirus disease (COVID-19). It is a pathogenic viral infection initiated from Huanan Seafood wholesale market of Wuhan (Hubei province, central China) on 31 December 2019, where seafood and live animals were sold (Huang, Wang, et al., 2020; Li, Guan, et al., 2020). This recent outbreak of novel CoV has expanded throughout China and spread rapidly around the whole world due to onward transmission (Lipsitch, Sverdlow, & Finelli, 2020). The virus was confirmed by Chinese authorities on 7 January 2020 (Lu, Stratton, & Tang, 2020; WHO, 2020a) and the transmission appeared to be from animals into human (Chan et al., 2020; Hui et al., 2020; Nishiura et al., 2020). The exact route of transmission is not clear yet. But the spike protein (S) may binds to ACE2 as an entry receptor for viral entry into the host cell and infects lung alveolar epithelial cells (Franquet, 2011; Kirchdoerfer et al., 2016; Xu, Chen, et al., 2020). After penetration into the body, all RNA-related machinery will be hacked. These viruses are responsible for diarrhea in pigs and cows and respiratory diseases in chickens. The animal-specific viruses are not normally infecting humans. But, may cause life-threatening pneumonia due to novelty of the virus, if they pass to humans. This is really very dangerous for the immune-suppressed individuals having diabetes, cardiovascular diseases and leads to pulmonary failure.

The important consequence of COVID-19 is pneumonia means this virus infects mainly respiratory system (Zhu, Zhang, et al., 2020). It may be transmitted through respiratory droplets and even via fecal-oral transmission (Chan et al., 2020; Wang, Cao, et al., 2020). That means the human coronaviruses are transmitted from one infected person to another mainly by direct contact through saliva, coughing or sneezing (within a range of about 1–1.5 m). Presently, there are no specific drugs or vaccines available for the treatment of human CoV (Hanh, Lin, Jin, & You, 2020). Therefore, it is very essential to understand the nature of this virus and its clinical characteristics. For this widespread zoonotic virus (Table 2), human-to-human transmission has been confirmed in more than 83 lakh cases of nearly 213 countries and territories as on 19 June 2020 (WHO, 2020). The common clinical symptoms for current COVID-19 are fever, dry cough, dyspnea, muscle soreness, headache, anosmia, and fatigue (Wang, Tang, & Wei, 2020). Initially, about 20% of cases were severe, and mortality rate was approximately 3% (Wang, Horby, Hayden, & Gao, 2020). For which, WHO has declared a global health emergency on 30 January 2020 (Mahase, 2020). It was too early to conclude the mortality rate. From the closed cases, the recent mortality rate is reached at ~9%, which may vary depending upon the current cases. Furthermore, the outbreak has destroyed the global economy and stock market. This is the seventh CoV which infect humans (Zhu, Zhang, et al., 2020) and other two are SARS and MERS. According to Jung et al., the current epidemic has a substantial potential for causing global pandemic $R_0 > 1$ (Jung et al., 2020). This study will make a brief report on 2019-nCoV, which may be helpful for the researchers as well as society.

### 1.1 Three important types of coronavirus which infect humans

#### 1.1.1 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)

SARS-CoV was the first infectious disease originated from Guangdong province of southern China in November 2002 and subsequently spread worldwide (Booth et al., 2003; Dwosh, Hong, Austgarden, Herman, & Schabas, 2003; Lee et al., 2003; Tsang et al., 2003; Weiss & Leibowitz, 2011; WHO, 2003). This acute and often severe CoV was spread via airborne droplets and through fomites (Donnelly et al., 2003), which have infected nearly 8,000 peoples with 778 deaths (WHO, 2003) before the episode was shutdown. The coronavirus virion structure (Finlay & Hancock, 2004) is shown in Figure 1. As per the phylogenetic analyses, it was placed in the early branch of betacoronaviruses category and the genus includes MHV (Snijder et al., 2003; Zhu & Chen, 2004). The patients infected by SARS-CoV, showed fever, sore throat, nonproductive cough, and myalgia in the first phase of the illness. In the second phase, dyspnea, hypoxia, and diarrhea...
| Name           | Type  | Year of finding | Key hosts       | Cellular receptor | Symptoms                                                                 | CT imaging                                                                 |
|---------------|-------|-----------------|-----------------|-------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 229E          | Alpha | 1966            | Bats            | Human aminopeptidase N (CD13) | Common cold, running nose, fever, headache, malaise, bronchiolitis, pneumonia (in neonates) | Bibasilar pleural effusions and diffuse consolidations plus GGOs             |
| NL63          | Alpha | 2004            | Bats, Palm Civets | ACE2               | Common cold, bronchiolitis/croup in children, fever, malaise, sore throat, cough and rhinitis | Acute upper respiratory tract infections                                    |
| OC43          | Beta  | 1967            | Cattle          | 9-O-Acetylated sialic acid | Common cold, running nose, fever, headache, malaise, bronchiolitis, pneumonia (in neonates) | Acute upper respiratory tract infections                                    |
| HKU1          | Beta  | 2005            | Mice            | 9-O-Acetylated sialic acid | Common cold, dyspnea, chronic respiratory disease | Acute upper respiratory tract infections                                    |
| SARS-CoV      | Beta  | 2002            | Bat, palm civets, raccoon dogs | ACE2 | Fever, headache, diarrhea, shivering, cough, dyspnea, pneumonia | Subpleural GGO and consolidation, interlobular septal and intralobular septal thickening |
| MERS-CoV      | Beta  | 2012            | Bat, camel      | DPP4               | Fever, dry cough, sore throat, dyspnea, pneumonia | Extensive GGO and occasional septal thickening and pleural effusions, basilar, bilateral, and subpleural airspace |
| SARS-CoV−2    | Beta  | 2019            | Bat, Pangolin (anteater) | ACE2 | Fever, dry cough, sore throat, short of breath, headache, myalgia, anosmia, rarely pneumonia | Multifocal patchy GGOs with subpleural distribution, Diffuse heterogeneous consolidation with GGO |
with continued fever became more prominent followed by severe lung damage. Deaths occurred from day 4 and severity of the disease increased with age, with mortality 50% for patients over 60 age (Booth et al., 2003; Lee et al., 2003; Tsui, Kwok, Yuen, & Lai, 2003).

Initially, it was suggested that Himalayan palm civets (Paguma larvata) and raccoon dogs (Nyctereutes procyonoides) as possible sources for human infections (Guan et al., 2003). But civets in the wild did not have evidence of infection with SARS-CoV and the discovery of SARS-like bat coronaviruses with approximately 90% sequence identity with SARS-CoV in Chinese horseshoe bats (Rhinolophus sinicus) suggests that this or a related species of bat is likely origin of SARS-CoV (Lau et al., 2005; Li et al., 2005). At early phases, the lungs of infected humans contained hyaline membranes, small vessel thrombi, edema, fibrin exudates, loss and sloughing of pneumocytes, and a mixed cellular infiltrate of lymphocytes. Whereas, at later phases, pneumonitis and consolidation with type II pneumocyte hyperplasia, squamous metaplasia and bronchiolitis obliterans was found (Beijing Group, 2003; Cameron et al., 2007; Wong et al., 2004).

### Table 2
Comparison between SARS-CoV, MERS-CoV, and SARS-CoV-2

| Name                                                       | Origin                      | Number of infected | Number of deaths | Number of countries | R₀ | Mortality (%) |
|------------------------------------------------------------|-----------------------------|--------------------|------------------|---------------------|----|---------------|
| SARS-CoV (Severe Acute Respiratory Syndrome)               | Guangdong, southern China   | 8,098              | 778              | 29                  | 2–4| 10            |
| MERS-CoV (Middle East Respiratory Syndrome)               | Jeddah, Saudi Arabia        | 2,434              | 876              | 27                  | 1  | 35.9          |
| SARS-CoV-2 (Severe Acute Respiratory Syndrome)            | Hubei, central China        | 8,385,440          | 4,50,686         | 213                 | 1.4–5.5 | ~9 (from the closed cases, till date) |

*R₀*: Basic Reproduction Number.
Ghanaian bats) were noticed in any of these tested livestock species. Hence, cattle, goat, donkey, sheep, and swine are not likely hosts of clade 2c coronaviruses. Sudan camels were rich with MERS-CoV antibodies, but no infections were observed in camel workers, other livestock, or bats (Farag et al., 2019). Kandeil et al., 2019 have conducted the surveillance studies on Middle East and African camels by collecting 4,027 nasal swabs and 3,267 serum samples to elucidate MERS-CoV infection and transmission. According to them, MERS-CoV RNA and antibodies were noticed in nasal swab samples collected from Tunisia, Senegal, Egypt, and Saudi Arabia. Lau et al., 2020 have reported the presence of MERS-CoV antibodies in Bactrian and hybrid camels in Dubai, UAE. In this study, the Bactrian camel serum samples collected from Xinjiang were tested negative for MERS-CoV antibodies.

Camels and bats have been identified as the potential source of virus for MERS-CoV. The role of spike protein (S) gene in virus attachment to host cells was examined (Sohrab & Azhar, 2019; Zumla, Chan, Azhar, Hui, & Yuen, 2016), which will be very valuable to design the therapeutic compounds and vaccines to prevent MERS-CoV disease. The schematic representation for the genome organization of human betacoronaviruses is shown in Figure 2. The antibody-based therapeutic modalities have received significant attention for the treatment of many diseases (Hu et al., 2019; Qiu et al., 2014; Zhu et al., 2006). Based on that, Wang et al., 2019 have reported the generation of antibody-peptide bispecific fusion proteins for clinical use. The efficacy of a ChAdOx1 MERS vaccine in dromedary camels (seronegative and seropositive) was studied by Alharbi et al., 2019. From the study, it was cleared that antibody responses in seropositive camels were enhanced by using a single dose of this vaccine.

1.1.3 Severe Acute Respiratory Syndrome SARS-CoV-2

The novel CoV (2019-nCoV) infection was initiated from Wuhan of China, in December 2019 (Lu, Stratton, et al., 2020) and has been spread to almost all countries. On 11 February 2020, WHO announced the name “COVID-19” for this epidemic disease caused by a new, viral, zoonotic pathogen 2019-nCoV. This virus was again renamed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (Gorbalenya et al., 2020). Also, WHO declared COVID-19 as the sixth public health emergency of international concern (PHEIC). SARS-CoV-2 is closely related to bat-SL-CoV-ZXC21 and bat-SL-CoVZC45 and spread by human-to-human transmission via droplets or direct contacts (Carlos, Dela Cruz, Cao, Pasnick, & Jamil, 2020; Chang et al., 2020; Li, Guan, et al., 2020; Wang, Hu, et al., 2020). Moreover, the hospital-related transmission was also suspected in 41% of patients (Wang, Hu, et al., 2020). The infection may have mean incubation period of 6.4 days and a basic reproduction number of 2.24–3.58. In this period, the patient may not display any symptoms (asymptomatic). The most common symptom for COVID-19 is fever, pneumonia followed by cough. As per computed tomography images of chest, bilateral lung involvement with GGO is the most common finding (Lai, Shih, Ko, Tang, & Hsueh, 2020).

Emerging infections were shown among pregnant women and their fetuses (Rasmussen & Hayes, 2005) with the increased risk of complications with H1N1 influenza (Sistone et al., 2010) and Zika virus (Moore et al., 2017; Rasmussen, Jamieson, Honein, & Petersen, 2016). Basing on that, Chen, Guo, et al., 2020 have reported the cesarean data for nine COVID-19 patients in their third trimester. The patients had

---

**FIGURE 2** Genome organization for human betacoronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2), (Adapted with Permission from Shereen et al., 2020, Journal of Advanced Research, © Elsevier BV.) [Colour figure can be viewed at wileyonlinelibrary.com]
fever (seven), fever with cough (four), myalgia (three), sore throat (two), and malaise (two). Fetal distress was also observed in two cases. Furthermore, five patients had lymphopenia and three patients had increased aminotransferase concentrations. Nine live births were recorded. No neonatal asphyxia was observed in newborn babies. Amniotic fluid, neonatal throat swab, cord blood, and breast milk samples were tested and found negative for the virus. The clinical characteristics of pregnant women were similar with non-pregnant patients. Since small number of cases analyzed, so more follow-up studies should be done to evaluate the safety and health of pregnant women having COVID-19 infection (Qiao, 2020). Zhu, Xu, et al. (2020)) have reported first time the clinical characteristics of a 52-year-old COVID-19 patient, who had received kidney transplantation 12 years ago. The overall clinical features were similar with non-transplanted COVID-19 patients. The patient was successfully recovered with low-dose methylprednisolone-based therapy. These data may be helpful for the future treatment of such type of patients.

The epidemic has spread from China to 212 countries and territories. According to WHO as on 19 June 2020, the number of confirmed cases of COVID-19 is 8,385,440 (WHO, 2020). The countries like USA, Brazil, Russia, India, UK, Italy, Spain, France, Germany, Turkey, Saudi Arabia, Peru, Chile, Pakistan, Mexico, Bangladesh, and Canada have reported more positive cases. The outbreak has killed 4,50,686 people to date. Moreover, Gilbert et al., 2020 have evaluated the preparedness and vulnerability of African countries against their risk toward COVID-19. As per their study, Algeria, Egypt, and South Africa have highest importation risk, whereas, Sudan, Angola, Nigeria, Ethiopia, Tanzania, Kenya, and Ghana have moderate risk. Hence, it is most important to provide necessary epidemiological data so that appropriate decisions are made regarding Paralympic Games, Tokyo 2020 Olympic and similar type of mass gatherings (Gallego, Nishiura, Sah, & Rodriguez-Moraes, 2020).

2 ENTRY MECHANISM OF HUMAN CORONAVIRUSES

To examine the possibilities of domestic animals as reservoir, serological studies were performed on sheep, goats, cattle, and chickens in Saudi Arabia, UAE, Jordan, and Europe. All samples tested seronegative for MERS-CoV (CDCP, 2016; Hemida et al., 2013; Meyer et al., 2015; Reusken, Ababneh, et al., 2013; Reusken, Haagmans, et al., 2013). But, dromedary camels are the primary animal host for MERS-CoV (Al-Tawfiq, 2013; Azhar, El-Kafrawy, et al., 2014; Chan et al., 2014; Reusken et al., 2016). And human-to-human transmission occurs by close contacts and droplets or due to nosocomial infection (Bauerfeind et al., 2016; Sabir et al., 2016). It is uncertain how COVID-19 transmission occurred from animals to humans. Initially, large numbers of infected people were linked to the wet animal market in Wuhan where live animals are routinely sold. So, it is suggested to be the zoonotic origin of the COVID-19. At beginning, two species of snakes identified as possible reservoir of the COVID-19. But, there is no consistent evidence of coronavirus reservoirs other than mammals and birds (Bassetti, Vena, & Giacobbe, 2020; Ji, Wang, Zhao, Zai, & Li, 2020). Genomic sequence analysis of COVID-19 showed similarity with two bat-derived SARS-like coronaviruses (Lu, Stratton, et al., 2020; Wan, Shang, Graham, Baric, & Li, 2020), indicating that mammals are the most likely link between COVID-19 and humans.

In the case of human-to-human transmission, the mechanism of transmission remains controversial (Chan et al., 2020; Li, Guan, et al., 2020; Phan et al., 2020) to some extent. The reports have suggested that human-to-human transmission is a likely route for spreading the novel CoV, which is supported by the cases that occurred within families or among the people who did not visit the wet animal market (Carlos et al., 2020; Wu, Hao, et al., 2020). Human-to-human transmission occurs via direct contact or through droplets spread by coughing or sneezing from an infected individual. In some cesarean cases of pregnant women having COVID-19 positive, there was no evidence for transmission from mother to child. Hence, it is not clear whether transmission can occur during vaginal birth or not. Moreover, no evidence of in utero transmission was seen in SARS or MERS to date (Rasmussen, Smulian, Lednicky, Wen, & Jamieson, 2020).

SARS-CoV-2 possesses spike protein, nucleocapsid protein, membrane glycoprotein, small membrane protein, and hemagglutinin esterase (Wu, Hao, et al., 2020; Zhou, Yang, et al., 2020). The spike protein contains a 3-D structure in the RBD region to maintain van der Waals forces (Xu, Chen, et al., 2020). The glycoprotein spikes present on the outer surface are mostly responsible for attachment and entry to the host cells (Figure 3). The RBD is loosely attached among viruses, so, the virus may infect multiple hosts (Perlman & Netland, 2009; Raj et al., 2013). SARS-CoV and MERS-CoV recognize exopeptidases as a key receptor for entry to human cells (Wang et al., 2013), while others mostly recognize aminopeptidases or carbohydrates. The entry mechanism of human coronavirus depends upon HAT and TMPRSS2, which splits spike protein and may establish further penetration changes (Bertram et al., 2011; Du et al., 2009). MERS coronavirus binds DPP4, while SARS-coronavirus binds ACE2 as a key receptor (Raj et al., 2013; Wang et al., 2013) and both are found in lung cells. Also, it is not clear whether COVID-19 is receiving ADE from other coronaviruses or not. We are at the beginning to understand the dynamics of COVID-19 in humans and its impact (Tetro, 2020). COVID-19 infection
has caused pulmonary, renal, cardiac, and circulatory damage that proves fatal in patients. Keeping in mind, Baig, Khaleeq, Ali, & Syeda, 2020 have investigated the involvement and possible contribution of neurological tissue damage to the morbidity and mortality caused by COVID-19.

3 | DIAGNOSIS OF COVID-19

A number of “unknown viral pneumonia” cases in China by a novel coronavirus (SARS-CoV-2) (Huang, Wang, et al., 2020; WHO, 2020c) were suddenly reported in December 2019. In just three months, this highly contagious virus has spread from Wuhan to almost all the continents. As the proper vaccination process for SARS-CoV-2 is not available, it is very important to identify it in early stage. By which immediate isolation of the infected person may be taken care from the healthy population. According to the latest guideline (trial sixth version) published by China government (General Office of National Health Committee., 2020), the diagnosis of COVID-19 should be confirmed by RT-PCR or gene sequencing for respiratory or blood specimens. Also, Chest CT is playing important role in the diagnosis of current COVID-19 detection in epidemic areas. Keeping in mind, Ai

---

FIGURE 3  Entry mechanism of human coronaviruses (Reproduced from Du et al., 2009, Nature reviews: Microbiology ©Springer Nature) [Colour figure can be viewed at wileyonlinelibrary.com]
et al., 2020 have reported the results of chest CT in comparison with RT-PCR results in 1,014 patients with suspected COVID-19. Bernheim et al., 2020 have analyzed chest CT findings in 121 infected patients in relationship to the time between symptom onset and the initial CT scan. In this study, they observed that certain CT findings are more common depending on the time course of infection. The reported chest imaging features of COVID-19 are similar with other types of CoV syndromes. Keeping in mind, Kooraki, Hosseiny, Myers, & Gholamrezaeeshad, 2020 have reported the precautions and safety measures for medical staff members to manage patients with suspected NCIP. Clinical diagnosis of COVID-19 is mainly based on epidemiological history, clinical manifestations, nucleic acid detection, CT scan, POCT of IgM/IgG, ELISA, and blood culture. CoV infections led to damage the lung and may cause pneumonia. In light of this, Li, Guan, et al., 2020 have discussed the current knowledge of diagnosis, treatment and molecular immune pathogenesis for COVID-19. The combining assessment of laboratory and clinical findings could be helpful for early diagnosis of COVID-19 pneumonia (Shi, Han, et al., 2020).

Radiologists are the first-line health care person, exposed directly to COVID-19 patients. The role of radiologists is given by Kim, 2020. According to him, with the detection of lung abnormality, they should suggest the disease severity and possible co-infection in other hospitalized patients. Lei, Li, Li, & Qi, 2020 have discussed the CT images in a 33-year-old woman. According to their study, the bilateralism of the peripheral lung opacities, without subpleural sparing, is the common CT findings of COVID-19 pneumonia. A low-cost and disposable colorimetric PAD should be developed for simple, rapid screening and detecting in infectious diagnostics. Such alternative approach of detection for MERS-CoV has also been developed (Teengam et al., 2017).

4 | TRAVEL RESTRICTIONS AND TRANSMISSIBILITY REDUCTION

The ongoing epidemic of COVID-19 is becoming unstoppable and has broken all previous records and declared pandemic by WHO (Callaway, 2020). Yang et al., 2020 have studied 149 confirmed patients in three tertiary hospitals of Wenzhou. 85 patients had Hubei residence/ travel history, 49 had contact with people of Hubei, and 15 had no travel/contact history. Most patients presented mild infection. Based on the rapid spread of this novel virus in Mainland China, Chinazzi et al., 2020 have reported a global metapopulation disease transmission model to understand the effect of travel limitations on transmission of this ongoing epidemic. Also, Dong, Du, & Gardner, 2020 have developed an interactive web-based dashboard to track COVID-19 in real time. This study was hosted by CSSE at Johns Hopkins University, USA, to visualize and track reported cases of COVID-19 in real time.

The Diamond Princess Cruise ship having 3,711 people was infected by SARS-CoV-2 (Ministry of Health, Labour and Welfare of Japan, 2020). A significant number of positive cases have been identified, which may be due to human-to-human transmission as there were limited space and high population density (Zhang, Diao, et al., 2020). The novel COVID-19 is highly contagious and is transmitted mostly through respiratory droplets. But, whether its transmission can be forwarded by touching a surface (ie, a fomite) is uncertain. Hence, a thorough understanding of the virus transmission should be essential as we know the transmission of MERS-CoV occurs mainly through nonhuman, zoonotic sources (camels, bats; Mobaraki & Ahmadzadeh, 2019). The proposed transmission mechanism of human CoV is shown in Figure 4.

Isolation of positive cases and contact tracing is used to control the outbreak. Keeping in mind, Hellewell et al., 2020 have used a mathematical model to assess whether isolation and contact tracing are really able to control the outbreak. Moreover, Rothana & Byrareddy, 2020 have reported the pathogenesis, phylogenetic analysis, epidemiology, symptoms, transmission, and future directions to control the onward transmission. The containment measures in China are successfully reducing transmission, which decreased the epidemic growth (Roosa et al., 2020). Such reduction is not the case elsewhere, and USA, Brazil, Italy, Spain, Germany, France, Russia, and India have been affected a lot (Remuzzi & Remuzzi, 2020; WHO, 2020). In these countries, a large number of asymptomatic carriers and mild patients may be present in the community. It is very important to identify and isolate them from healthy population (Hu et al., 2020). As we all know that prevention is better than cure, preventing and controlling the outbreak must be focused on the early isolation of patients and quarantine from close contacts in families and healthy population (Tian, Hu, et al., 2020). Moreover, social distancing will play a positive effect to control the outbreak as it will decrease the community transmission.

5 | SYMPTOMS OF COVID-19 INFECTION

The symptoms of novel COVID-19-infected pneumonia appear after an incubation period of ~5.2 days (Li, Guan, et al., 2020). The common symptoms for COVID-19 are identified by fever, dry cough, headache, fatigue, anosmia, and dyspnea. But in second phase, other symptoms such as sputum production, haemoptysis, diarrhea, and
lymphopenia will be observed (Carlos et al., 2020; Huang, Wang, et al., 2020; Ren et al., 2020; Wang, Tang, et al., 2020). The clinical features of chest CT scan revealed pneumonia, RNAaemia, acute cardiac injury, and GGOs (Huang, Wang, et al., 2020).

Both SARS-CoVs enter the cell via ACE2 receptor (Wan et al., 2020; Zhou, Yang, et al., 2020). The SARS-Cov-2 first infects lower airways and binds to ACE2 (found in lung) on alveolar epithelial cells. Both viruses activate immune cells and induce the secretion of inflammatory cytokines and chemokines. The “cytokine storm” is the proposed mechanistic theory for organ damage, which leads to death (Jiang et al., 2020). The period of death ranged from 6 to 41 days from the onset with a median of 14 days (Wang, Tang, et al., 2020). This depends on the age and immune system of the patient.

6 | POSSIBLE VACCINES FOR COVID-19 PNEUMONIA

No approved vaccines or specific treatments are yet available against SARS-CoV, MERS-CoV infection for potential therapy of humans. So many researchers are trying to develop a vaccine using a variety of platforms (Graham, Donaldson, & Baric, 2013; Kato et al., 2019; Schindewolf & Menachery, 2019). It may take months and years to develop particular vaccines for such a rapidly mutating SARS-CoV-2 as these studies are in progress and more laboratory and clinical trials still should be explored. Furthermore, antigen presentation may be affected by CoV (Menachery et al., 2018). According to WHO, minimum 18 months required for the development of COVID-19 vaccines (Huaxia, 2020).

Since SARS-CoV-2 is a kind of RNA virus, so it possesses some similar functional proteins as of HIV. Hence, the HIV protease inhibitors may be effective for potential therapy of humans. Recently, lopinavir/ritonavir (LPV/r) combination has been recommended for the treatment of COVID-19 pneumonia. This combination was previously confirmed for the effective treatment of MERS-CoV and SARS-CoV (Chu et al., 2004; Momattin, Al-Ali, & Al-Tawfiq, 2019). Baricitinib may be suggested as a potential drug for COVID-19 treatment which might reduce the process of both virus invasion and inflammation (Richardson et al., 2020). As per molecular docking studies, another anti-HIV drug nefllnivir was anticipated to be active against SARS-CoV-2 (Xu, Peng, et al., 2020). Remdesivir and chloroquine could inhibit COVID-19 infection in vitro (Wang, Cao, et al., 2020). Moreover, Arbidol has a broad-spectrum antiviral activity against respiratory viruses. The clinical trials of safety and efficacy of these drugs are going on. In addition, SARS-CoV-specific human mAb (CR3022) could bind potently with 2019-nCoV receptor-binding domain (Tian, Li, et al., 2020). So, CR3022 should be developed to prevent and treat new coronavirus infections.

It is also reported that 75 patients were treated by using 75 mg oseltamivir, 500 mg lopinavir, 500 mg ritonavir, and
0.25 g ganciclovir (intravenous) for 3–14 days (Chen, Guo, et al., 2020; Chen, Zhou, et al., 2020). Moreover, one patient treated by lopinavir/ritonavir showed improvements in his chest radiographs after four days (Huang, Tu, et al., 2020). This combination was also reported by Bhatnagar et al., 2020 with the protocol as per the guidelines of ICMM and WHO (WHO, 2020d). Also, a case of COVID-19 pneumonia is responding well to remdesivir in USA, which is now undergoing a clinical trial in China (Cao, Deng, & Dai, 2020; Lai et al., 2020). Hence, it may be used as a possible therapeutic option for COVID-19 pneumonia (Al-Tawfiq, Al-Homoud, & Memish, 2020; Ko et al., 2020). The safety and efficacy of chloroquine for the treatment of COVID-19 are discussed by Cortegiani, Ingoglia, Ippolito, Giarratano, & Einav, 2020. Furthermore, hydroxychloroquine may be effective in inhibiting COVID-19 infection due to less toxic nature (Liu, Cao, et al., 2020; Liu, Xiao, et al., 2020; Sivabakya & Srinivas, 2020). Caly, Druce, Catton, Jans, & Wagstaff, 2020 have also reported recently that the anti-parasitic Ivermectin inhibits the replication of SARS-CoV-2 in vitro. The ongoing advances in designing vaccines and therapeutics to counter COVID-19 pneumonia have been highlighted by Dhma et al., 2020. Moreover, Lin, Lu, Cao, & Li, 2020 have recommended high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy as an effective treatment for severe and critical type patients. In addition, some recent clinical trials on drug repositioning for COVID-19 pneumonia treatment were also listed (Fisher & Heymann, 2020; Rosa & Santos, 2020). The novel virus may damage the central nervous system of the patient (Zhou, Zhang, Wang, & Gao, 2020). In that case, the health workers should focus on intensive care. The combined effect of hydroxychloroquine and ivermectin is also suggested by Patri & Fabbrocini, 2020. But there is no in vitro evidence reported on the combined effect. Moreover, sitagliptin may be useful for the patients having pre-existing cardiovascular and (or) diabetic issues (Bardaweel, Hajjo, & Sabbah, 2021). Due to the involvement of immune hyperactivation and ARDS in fatal cases of COVID-19, anti-rheumatic drugs such as hydroxychloroquine and tocilizumab have been proposed by Zhong, Tang, Ye, & Dong, 2020 as potential therapies for the treatment of COVID-19. Triple antiviral therapy with lopinavir–ritonavir, interferon beta-1b, and ribavirin were safe and superior to lopinavir–ritonavir alone for mild to moderate COVID-19 patients (Hung et al., 2020). In addition, Teicoplanin, an antibiotic exhibited significant efficacy to inhibit the first stage of MERS-CoV previously. Its activity may be beneficial against this novel virus (Baron, Devaux, Colson, Raoult, & Rolain, 2020). Some existing drugs (Figure 5) used against COVID-19 infection are listed in Table 3. However, more research is urgently needed to identify novel chemotherapeutic drugs for treating and controlling COVID-19 infections. Several clinical trials are going on to assess the adequacy of therapeutic agents (Menni, Sudre, Steves, Ourselin, & Spector, 2020). Such drugs will help to reduce the morbidity and mortality, whereas, prophylactics and vaccines will prevent further disease transmission (Park, Thwaites, & Openshaw, 2020).

CoV is biologically diverse and rapidly mutating. So, anticornavirus therapy is somewhat challenging. Zhang, Lin, et al. (2020)) have designed some broad-spectrum antiviral compounds and suggested to exhibit excellent properties against MERS-CoV, SARS-CoV, and the novel BetaCoV/Wuhan/2019 as well. Loczechin et al., 2019 have reported the antiviral activity of seven different CQDs for the treatment of human coronavirus infections. In addition, Suwannarach et al., 2020 have also studied the immunomodulatory activities of fungal bioactive compounds as potential therapeutic agents against CoV. Liu, Zhou, et al., 2020 have discussed some patents disclose methodologies for treating and preventing CoV infections, which may be applicable to COVID-19. As respiratory failure is the most important findings of COVID-19, attention should be given for critically ill patients during mechanical ventilation in hospitals (Linga, Joyna, Lipman, Constantine, & Joannes-Boyau, 2020). Till date, more than 500 clinical trials (randomized/ non-randomized) were registered with standard of care. Other trials are also enrolling over remdesivir, IL-6 inhibitors (tocilizumab and sarilumab), stem-cell therapy, convalescent plasma therapy, corticosteroids, vaccine candidates, direct-acting antiviral drugs, and traditional Chinese medicines. Most of these trials are giving comparative efficacy (Table 3) (Thorlund et al., 2020; Tu et al., 2020). In addition, six vaccine candidates namely mRNA (NCT04283461), aAPC (NCT04299724), DNA (NCT04336410), a lentiviral vector (NCT04276896), chimpzee adenoviral vector ChAdOx1 (NCT04324606), and adenoviral vector 5 (NCT04313127) have entered phase I clinical trials to assess their safety and immunogenicity (Kim, Dema, & Reyes-Sandoval, 2020).

7 | ZOONOTIC TRANSMISSION

Although it was believed that bats and pangolins were potential hosts for SARS-CoV-2 transmission, but the origin of SARS-CoV-2 remains unclear and the evidence of transmission from animals to human is not established with certainty (Zhai, Wei, Lv, Xu, et al., 2020). As reported earlier, the initial infected individuals had a common exposure spot; Wuhan Seafood wholesale market of China, where various domestic animals, wild animals and live animals including poultry, bats, rabbits, turtles, marmots, pangolins, and snakes were sold for human consumption (Hui et al., 2020; Ji et al., 2020; Lu et al., 2020). The Chinese people are...
commonly consumed wild animal meat and their products due to their believed medicinal value and health promoting effects (Harypursat & Chen, 2020). So, the host range now gets expanded and it is very essential to understand the risks to other animals and possible zoonotic transmission.

On 28 February 2020, a 17-year-old Pomeranian dog in Hong Kong had tested positive as stated by Agriculture, Fisheries and Conservation Department (AFCD) (AFCD, 2020). The dog had initially tested negative for antibodies specific to COVID-19 as antibody formation may take 14 days or more (Almendros, 2020a). Since then, another case was reported in a two-year-old German shepherd dog on 19 March (AFCD, 2020a, 2020b). In both the cases, the dogs were living in close contact with SARS-CoV-2 positive owners (American Veterinary Medical Association, 2020). After that, AFCD of Hong Kong had conducted tests on 17 dogs and 8 cats, out of which only two dogs had tested positive. Both dogs later tested negative on RT-PCR, which is the most sensitive test for the diagnosis of COVID-19 (Wang, Kang, Liu, & Tong, 2020). This study supported human-to-animal transmission. But it is still not confirmed that dogs can transmit this virus to human beings (Almendros, 2020b).

On 31 March, a cat had tested positive on RT-PCR from oral, nasal, and fecal samples in Hong Kong by the GHKSAR (GHKSAR, 2020). Furthermore, a cat tested positive at the University of Liège in Belgium. After this issue, Shi, Wen, et al., 2020; Shi, Han, et al., 2020 have reported an experimental infection of a number of companion and domestic animals by using two SARS-CoV-2 viruses isolated from environment and human COVID-19 patient. They confirmed that cats and ferrets are highly susceptible to COVID-19 (Li, 2020). They also suggested that SARS-CoV-2 was transmitted in cats via respiratory droplets. Moreover, cats in Wuhan were infected with SARS-CoV-2 during the outbreak, which clearly suggested true infection in them (Zhang, Wang, Qi, Shen, & Li, 2020). The infected cats may transmit the virus to other animals living in close contact with them (Martina et al., 2003). The first human to nondomestic animal transmission was reported in New York City, where a tiger was surprisingly infected by a positive asymptomatic zookeeper (USDA, 2020). Hence, it is suggested that the owners should adopt appropriate precautions and keep a suitable distance from the animals to prevent the spread of this virus (Rodriguez-Morales, Dhama, Sharun, Tiwari, &
Due to the broad host range, the virus keeps on circulating between vertebrates, various animal species, and humans (Tiwari et al., 2020). The wide host range of this novel virus is believed to be due to instability of the replicase enzyme, RNA-dependent RNA polymerase, O-linked glycans, polybasic furin cleavage site, higher rate of mutations, and genetic recombination (Chen, 2020; Patel & Jernigan, 2020). Initially, it was believed that bats or pangolins are the probable sources of origin of this novel virus (Andersen, Rambaut, Lipkin, Holmes, & Garry, 2020; Wu, Zhao, et al., 2020; Zhang, Wu, & Zhang, 2020). But the actual intermediate host and the nature are yet to be explored.

Basic research on SARS-CoV-2 is essential to support the process of development of the therapeutic agents. It is useful to realize some models that can authentically imitate the comportments of coronavirus and reproduce the pathology of COVID-19 (Takayama, 2020). Here, we enumerated briefly the applicable models: cell lines, organoids, and animal models.

### Cell lines and organoids for SARS-CoV-2

The in vitro cell model can offer valuable information about the virus infection. The cell lines (Human airway epithelial, Vero E6, Caco-2, Calu-3, HEK 293T, Huh 7) and

---

**TABLE 3** Some existing drugs for the possible use against COVID-19

| Sl. No. | Name of the drug | Possible mechanism | Disease | Trials, clinical studies, outcome |
|---------|------------------|--------------------|---------|----------------------------------|
| 1       | Lopinavir        | May inhibit the viral proteases | HIV infection | No benefit, In combination Lopinavir and Ritonavir not found to improve COVID-19 patients |
| 2       | Ritonavir        | May increase the levels of other protease inhibitors | HIV infection | In vitro study revealed no benefit |
| 3       | Darunavir        | Act as an antiretroviral protease inhibitor | Ebola infection | Potential benefit found in preliminary results |
| 4       | Remdesivir       | May block viral nucleotide synthesis to stop viral replication | Ebola, hepatitis C, Marburg virus | In vitro experiments suggest benefits |
| 5       | Galidesivir      | May lead to the structural change in the viral enzyme and results premature termination of the elongating RNA | Hepatitis C, RSV infection | Results awaited |
| 6       | Ribavirin        | May inhibit viral mRNA polymerase and leading to a decrease in viral replication (or production of defective virions) | Malarial infection | Potential benefit |
| 7       | Chloroquine      | May elevate endosomal pH and interfere with ACE2 glycosylation | Helminthic and protozoal infection | Potential benefit |
| 8       | Nitazoxanide     | May inhibit viral protein expression | influenza infection | No benefit |
| 9       | Arbidol (Umifenovir) | May prevent viral entry to the target cell | Anti-parasitic agent, anti-HIV | Results awaited |
| 10      | Ivermectin       | Viral Protease | Antimalarial and antiinflammatory Agent | Mixed, No benefit |
| 11      | Hydroxychloroquine | Blocking Virus–Cell Membrane Fusion | Antimalarial and antiinflammatory Agent | Mixed, No benefit |
| 12      | Tocilizumab      | IL-6 inhibition | Inflammation, cytokine release syndrome (CRS) | Potential benefit |
| 13      | Glucocorticosteroids | Downregulation of inflammatory cytokines | Allergy, hypersensitivity, autoimmune diseases | No benefit |
| 14      | Intravenous immunoglobulin (IVIG) | Pleiotropic immunomodulation | anti-inflammatory and cytoprotective | Potential benefit |
organoids (human bronchial, human lung, human kidney, human liver ductal, human intestinal, human blood vessel) are a method to study the virus and the interactions inside host cells (Takayama, 2020).

- Animal models for SARS-CoV-2

Animal models are providing significant contributions to evaluate the vaccines for a particular disease. It will help in understanding the disease process and developing prophylactics and therapeutics (Dhama et al., 2020). The pathology of COVID-19 can be replicated and observed in a tissue-specific by using animal models. Small animals (wild-type mice, human ACE2 transgenic mice, Syrian hamsters) and large animals (ferrets, cats, Cynomolgus macaques, Rhesus macaques) are being used for evaluating vaccines and drugs against SARS-CoV-2 (Takayama, 2020; Tiwari et al., 2020). Rhesus macaques displayed high virus amount in oral-naso and rectal swabs while working on SARS-CoV-2. In studying the pathogenesis of the disease, the apparent lesions and clinical signs contribute significantly in developing vaccines and antivirals (Munster et al., 2020).

Golden Syrian hamsters were suggested to be the promising animal model when investigated against SARS type strains for revealing CoV pathology and pathogenesis (Roberts et al., 2008). Furthermore, transgenic mice are now considered to be compatible model for SARS-CoV-2 but initially, mice were challenging due to the difference in receptor ACE2 usage pattern (Liu, Cao, et al., 2020; Liu, Cao, et al., 2020; Liu, Zheng, et al., 2020; Liu, Xiao, et al., 2020; Wang, Tang, et al., 2020; Zhou, Yang, et al., 2020). On modeling cats, ferrets, pigs, orangutans, monkeys, bats, and humans are akin based on the structural similarity of their ACE2 receptors (Jarvis, 2020). Hence, these may contribute significantly as animal models to investigate further studies.

9 | IMMUNOTHERAPY

As there are no approved vaccines or antiviral therapeutic agents for the treatment of COVID-19, the existing pieces of evidence are discussed herewith. It is suggested that immunotherapy is an efficient therapeutic option against the infected patients (Jafari & Ghasemi, 2020). Acute respiratory distress syndrome (ARDS) can induce the apparition of other complications, including secondary bacterial infection and lung fibrosis. Recent clinical data have led to the conclusion that severe COVID-19 is determined by an over reactive immune response leading to a cytokine storm and the development of ARDS (Bonam, Kaveri, Sakuntabhai, Gilardin, & Bayry, 2020). For severe cases, host-directed immunotherapy is an adjunct therapy to reduce inflammation and inflammation-associated lung damage and to prevent ICU hospitalization. Several immunotherapeutic strategies targeting either inflammatory mediators, or passively neutralize SARS-CoV-2, or prevent them from viral entry are under evaluation (Bonam et al., 2020; Groß, Jahn, Cushman, Bär, & Thum, 2020; Jafari & Ghasemi, 2020; Shih, Wu, Tu, & Chi, 2020).

Till date, all immunotherapy attempts for this novel virus comprise ACE2 immunoadhesin, immunoglobulins, polypeptide hormone for maturation of T cells, a monoclonal antibody against interleukin-6 (IL-6) and polyclonal antibody by plasma therapy. Immunoglobulins and plasma therapy intervention for SARS-CoV-2 infected patients could improve clinical outcomes (Jafari & Ghasemi, 2020). Moreover, to block the virus entry and attachment, monoclonal antibodies are preferred due to their purity, specificity, safety, low risk of blood-borne pathogen contamination (Shambugaraj, Siriwattananon, Wangkanont, & Phoolcharoen, 2020). ACE2 immunoadhesin has not been tested yet. Some of these methods were discussed in a clinical trial study reported by Zhang, Zhang, et al. (2020)).

Most of the COVID-19 patients were observed to have increased in IL 6, leading to lung tissue damage. The same elevated serum levels of IL-6, TNF-α, and IFN-γ were observed in cytokine release syndrome (CRS). Interleukin-6 (IL-6) acts as both anti-inflammatory myokine and pro-inflammatory cytokine. A rapid resolution of CRS symptoms in COVID-19 patients has to target either IL-6 receptor (tocilizumab, a recombinant humanized monoclonal antibody) or IL-6 (siltuximab, a chimeric monoclonal antibody) to avoid the pulmonary edema, hypotension, and cardiac dysfunction (Le et al., 2018). Human monoclonal antibody (sarilumab), Anti-IL-6 receptor antibodies (tocilizumab), and anti-IL-6 antibody (siltuximab) are under evaluation in different centers (Baruah & Bose, 2020; Kruse, 2020; Liu, Zhang, et al., 2020). ASCIA recommends that tocilizumab may be considered as an off-label treatment option for the patients with ARDS, and its clinical trials.

Furthermore, other interventions such as nanoparticles, viral-vectors, and corticosteroids were also suggested for SARS-CoV-2. In this contest, Liao et al., 2020 have discussed the bronchialveolar immune microenvironment design underlying immunopathogenesis in COVID-19. Reis & Lima, 2020 have proposed a modified version of the CHA2DS2-VASc score to reduce thromboembolic complications before the condition becomes severe. WHO advised “Do not routinely give systemic corticosteroids for the treatment of viral pneumonia outside clinical trials” (WHO, 2020d). However, ASCIA supports its use because the available data were generally low quality with small patient numbers (ASCIA, 2020). In addition, Klimk et al., 2020 have suggested the allergen-specific immunotherapy (AIT) that confers a long-term clinical benefit (activates immune tolerance responses) for the diseases like allergic rhinoconjunctivitis, allergic bronchial asthma,
etc. (Bousquet, Lockey, & Malling, 1998; Jutel et al., 2013). The immune mechanisms in AIT and COVID-19 were also discussed (Klimek et al., 2020). This report may provide ample references for the researchers to develop vaccines and antivirals against this novel emerging virus.

10 | CONCLUSIONS

This manuscript has discussed various elements of COVID-19 infection and its onward transmissions. After originating from Wuhan, this zoonotic virus has spread rapidly to 213 countries and territories in the globe and causing SARS in humans, which forced to declare it “Pandemic” by WHO, as $R_0 > 1$. As per the laboratory confirmed positive cases, respiratory failure is the most common findings of COVID-19. But the common symptoms are dry cough, fever, headache, loss of smell or taste, muscle pain, dyspnea, diarrhea, and pneumonia. This recent outbreak believed to be originated from bats and has resulted 4,50,686 deaths as on 19 June 2020 due to human-to-human transmission. Due to this onward transmission, more than 83 lakh positive cases are found in the globe till date and still increasing rapidly. Some countries are trying to fight by preventing community transmission to control the outbreak. Due to unclear mechanism for COVID-19 transmission, it is difficult to develop evidence-based infection control protocols to prevent community transmissions. According to the latest guideline published by China government, the diagnosis of COVID-19 should be confirmed by RT-PCR or gene sequencing for respiratory or blood specimens. Furthermore, Chest CT is playing a vital role in early detection of current COVID-19 pneumonia. The clinical features of chest CT scan revealed pneumonia, RRAemia, acute cardiac injury, and GGOs. Some patients may present normal chest finding despite of testing COVID-19 positive.

As there are no specific vaccines available against COVID-19 infection, the treatment may be carried out by using available broad-spectrum antiviral drugs like nucleoside analogues and HIV protease inhibitors. Lopinavir/ritonavir (LPV/r) combination has been recommended for the treatment. The broad-spectrum antiviral remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection. Also, the combined effect of hydroxychloroquine and ivermectin will play important rule in inhibiting 2019-nCoV infection. It is also suggested that hydroxychloroquine and azithromycin may be useful for the early treatment of patients. Another most important thing is “isolation of positive cases, contact tracing, and social distancing will be very helpful to control the outbreak”. In this contest, Chu et al., 2020 have suggested that physical distancing, face masks, and eye protection to prevent person-to-person transmission. According to Hibberd, “If you can identify and quarantine most of the positive cases, then you do not have to lockdown everyone else” (Burki, 2020). Furthermore, we may boost our immunity with Tinospora cordifolia (Guduchi) as recommended by Ayurveda, India. In addition, preventives (Arsenic album) may be used as suggested by Department of Ayush, Government of India. This review presents a strong intellectual background on the origin, transmission, symptoms, diagnosis, possible vaccines, animal models, and immunotherapy for this novel COVID-19 pneumonia, which gives an in-depth insight into several aspects of this global pandemic and will provide ample references for the researchers as well as society. Moreover, the information’s included in this review may be useful for the ongoing development of therapeutic agents and vaccines and also preventing the spread of this disease.

ACKNOWLEDGMENTS

The authors are highly thankful to the editor and reviewers for their valuable and constructive suggestions to modify the manuscript. RKM is also thankful to Principal, Government College of Engineering, Keonjhar, for his help and facilities.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest in this work.

DATA AVAILABILITY STATEMENT

Not applicable.

ORCID

Ranjan K. Mohapatra https://orcid.org/0000-0001-7623-3343
Lucia Pintilie https://orcid.org/0000-0002-1036-7653

REFERENCES

AFCD. (2020a). Pet dog tests positive for COVID-19 virus. Retrieved from www.afcd.gov.hk/english/publications/pr2343.html
AFCD. (2020b). Blood test result of pet dog with low-level infection of COVID-19 released. Retrieved from www.afcd.gov.hk/english/publications/pr2342.html
AFCD. (2020c). Low-level of infection with COVID-19 in pet dog. Retrieved from www.afcd.gov.hk/english/publications/pr2343.html
Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., … Xia, L. (2020). Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology, In press. https://doi.org/10.1148/radol.2020200642
Alharbi, N. K., Qasim, I., Almasoud, A., Aljami, H. A., Alenazi, M. W., Alhafufi, A., … Balkhy, H. H. (2019). Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Scientific Reports, 9, 16292. https://doi.org/10.1038/s41598-019-45730-4
Almendros, A. (2020b). Can companion animals become infected with Covid-19? The Veterinary Record, 186(12), 388–389. https://doi.org/10.1136/vr.m1194
Chang, D., Lin, M., Wei, L., Xie, L., Zhu, G., Dela Cruz, C. S., … Sharma, L. (2020). Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan. China. JAMA, 323(11), 1092–1093. https://doi.org/10.1001/jama.2020.1623

Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., … Zhang, Y. (2020). Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet, 395, 809–815. https://doi.org/10.1016/S0140-6736(20)30360-3

Chen, J. (2020). Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes and Infection, 22(2), 69–71.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., … Zhang, L. I. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7

Chinaazzi, M., Davis, J. T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., … Vespignani, A. (2020). The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. https://doi.org/10.1126/science.aba9757

Chu, C. M., Cheng, V. C. C., Hung, I. F. N., Wong, M. M. L., Chan, K. H., Chan, K. S., … Yuen, K. Y. (2004). Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax, 59, 252–256. https://doi.org/10.1136/thorax.2003.012658

Chu, D. K., Akl, E. A., Duda, S., Solo, K., Yacoub, S., Schünemann, H. J., … Schünemann, H. J. (2020). On behalf of the COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. The Lancet, 395(10242), 1973–1987. https://doi.org/10.1016/S0140-6736(20)31142-9

Conzade, R., Grant, R., Malik, M., Elkholy, A., Elhakim, M., Samhouri, D., … Van Kerkhove, M. (2020). Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases. Viruses, 10(8), 425. https://doi.org/10.3390/v10080425

Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care, 57, 279–283. https://doi.org/10.1016/j.jcrc.2020.03.005. And the references therein.

Dham, A., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chiaicumpa, W. (2020). COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, 16(6), 1232–1238. https://doi.org/10.1080/21645515.2020.1735527

Donnely, C. A., Ghani, A. C., Leung, G. M., Hedley, A. J., Fraser, C., Riley, S., … Anderson, R. M. (2003). Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet, 361, 1761–1766. https://doi.org/10.1016/S0140-6736(03)13410-1

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009). The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nature Reviews Microbiology, 7(3), 226–236. https://doi.org/10.1038/nrmicro2090

Dwosh, H. A., Hong, H. H., Austgarden, D., Herman, S., & Schabas, R. (2003). Identification and containment of an outbreak of SARS in a community hospital. CMAJ, 168, 1415–1420.

El-Duaih, P., Sylverken, A., Owusu, M., Yeboah, R., Lampet, J., Frimpong, Y. O., … Adu-Sarkodie, Y. (2019). Potential intermediate hosts for coronavirus transmission: No evidence of Clade 2c coronaviruses in domestic livestock from Ghana. Tropical Medicine and Infectious Disease, 4, 34. https://doi.org/10.3390/tropicalme d4010034

Falzarano, D., Kamissoko, B., de Wit, E., Maiga, O., Cronin, J., Samaké, K., … Feldmann, H. (2017). Dromedary camels in northern Mali have high seropositivity to MERS-CoV. One Health, 3, 41–43. https://doi.org/10.1016/j.onehlt.2017.03.003

Farag, E., Sikkema, R. S., Mohamedani, A. A., de Bruin, E., Munnink, B. B. O., Chandler, F., … Elrahman, S. H. A. (2019). MERS-CoV in camels but not camel handlers, Sudan, 2015 and 2017. Emerging Infectious Diseases, 25(12), 2333–2335. https://doi.org/10.3201/ eid2512.190882

Finlay, B. B., & Hancock, R. E. (2004). Can innate immunity be enhanced to treat microbial infections? Nature Reviews Microbiology, 2, 497–504.

Fisher, D., & Heymann, D. (2020). Q&A: The novel coronavirus outbreak causing COVID-19. BMC Medicine, 18, 57. https://doi.org/10.1186/s12916-020-01533-w

Franquet, T. (2011). Imaging of pulmonary viral pneumonia. Radiology, 260(1), 18–39. https://doi.org/10.1148/radiol.11092149

Gallego, V., Nishiura, H., Sah, R., & Rodriguez-Moraes, A. J. (2020). The COVID-19 outbreak and implications for the Tokyo 2020 Summer Olympic Games. Travel Medicine and Infectious Disease, 34, 101604. https://doi.org/10.1016/j.tmaid.2020.101604

General Office of National Health Committee. (2020). Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial sixth edition) (2020–02–18).

GHKSA (2020). Pet cat tests positive for COVID-19 virus. Retrieved from www.info.gov.hk/gia/general/202003/31/P2020033100717.html

Gilbert, M., Pullano, G., Pinotti, F., Valdano, E., Poletto, C., Boëlle, P.-Y., … Colizza, V. (2020). Preparedness and vulnerability of African countries against importations of COVID-19: A modelling study. Lancet, 395, 871–877. https://doi.org/10.1016/S0140-6736(20)30411-6

GISAID: Global Initiative on Sharing All Influenza Data (2020). Phylogeny of SARS-like beta coronaviruses including novel coronavirus (nCoV). Retrieved from https://nextstrain.org/groups/blab/sars-like-cov

Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., … Ziebuhr, J. (2020). Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. bioRxiv. https://doi.org/10.1101/2020.02.07.937862

Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013). A decade after SARS: Strategies for controlling emerging coronaviruses. Nature Reviews Microbiology, 11, 836–848. https://doi.org/10.1038/nrmic ro2093

Groß, S., Jahn, C., Cushman, S., Bär, C., & Thum, T. (2020). SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Journal of Molecular and Cellular Cardiology, 144, 47–53. https://doi.org/10.1016/j.yjmcc.2020.04.031
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., … Poon, L. L. M. (2003). Isolation and characterization of viruses related to the sars coronavirus from animals in Southern China. Science, 302, 276–278. https://doi.org/10.1126/science.1087139

Han, Q., Lin, Q., Jin, S., & You, L. (2020). Coronavirus 2019-nCoV: A brief perspective from the front line. Journal of Infection, 80, 373–377. https://doi.org/10.1016/j.jinf.2020.02.010

Hansell, D. M., Bankier, A. A., MacMahon, H., MeCloud, T. C., Müller, N. L., & Fleischner, R. J. (2008). Society: Glossary of terms for thoracic imaging. Radiology, 246(3), 697–722. https://doi.org/10.1148/radiol.2462070112

Harypursat, V., & Chen, Y. K. (2020). Six weeks into the 2019 coronavirus disease (COVID-19) outbreak- it is time to consider strategies to impede the emergence of new zoonotic infections. Chinese Medical Journal (Engl), 133(9), 1118–1120.

Hellewell, J., Abbott, S., Gimma, A., Bosse, N. I., Jarvis, C. I., Russell, T. W., … van Zandvoort, K. (2020). Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health, 8, e488–e496. https://doi.org/10.1016/S2214-109X(20)30074-7

Hemida, M., Perera, R., Wang, P., Alhammadi, M., Siu, L., Li, M., … Peiris, M. (2013). Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Eurosurveillance Weekly, 18(50), 20659. https://doi.org/10.2807/1560-7917.es2013.18.50.20659

Hu, D., Zhu, Z., Li, S., Deng, Y., Wu, Y., Zhang, N., … Ying, T. (2019). A broadly neutralizing germine-like human monoclonal antibody against dengue virus envelope domain III. PLoS Path, 15, e1007836. https://doi.org/10.1371/journal.ppat.1007836

Hu, Z., Song, C. I., Xu, C., Jin, G., Chen, Y., Xu, X., … Shen, H. (2020). Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci, 63, 706–711. https://doi.org/10.1007/s11427-020-1661-4

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. I., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Huang, Y., Tu, M., Wang, S., Chen, S., Zhou, W., Chen, D., … Guo, L. (2020). Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Medicine and Infectious Disease, 101606. https://doi.org/10.1016/j.tmaid.2020.101606

Huaxia. (2020) WHO says vaccines against novel coronavirus 18 months away, pushes global research. 2020. Xinhuanet. Retrieved from http://www.xinhuanet.com/english/202002/12/c_138777886.htm

Hui, D. S., Azhar, E. I., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., … Petersen, E. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264–266.

Hung, I.-N., Lung, K.-C., Tso, E.-K., Liu, R., Chung, T.-H., Chu, M.-Y., … Yuen, K.-Y. (2020). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. The Lancet, 395(10238), 1695–1704. https://doi.org/10.1016/S0140-6736(20)31042-4

Jafari, A. A., & Ghasemi, S. (2020). The possible of immuno-therapy for COVID-19: A systematic review. International Immunopharmacology, 83, 106455. https://doi.org/10.1016/j.imsimp.2020.106455

Jarvis, C. (2020). Mar 16, 2020 which species transmit Covid-19 to humans? we’re still not sure. [Accessed 2020 April 1). Retrieved from https://www.the-scientist.com/news-opinion/which-species-transmit-covid-19-to-humans-were-stillinnot-sure-67272

Ji, W., Wang, W., Zhao, X., Zai, J., & Li, X. (2020). Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. Journal of Medical Virology, 92(4), 433–440. https://doi.org/10.1002/jmv.25682

Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., & Xia, Z. (2020). Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of General Internal Medicine, 35(5), 1545–1549. https://doi.org/10.1007/s11367-020-05762-w

Jung, S.-M., Akhmetzhanov, A. R., Hayashi, K., Linton, N. M., Yang, Y., Yuan, B., … Nishiura, H. (2020). Real-time estimation of the risk of death from novel coronavirus (COVID-19) Infection: Inference using exported cases. Journal of Clinical Medicine, 9, 523. https://doi.org/10.3390/jcm90200523

Jutel, M., Van de Veen, W., Agache, I., Azkur, K. A., Ackis, M., & Ackis, C. A. (2013). Mechanisms of allergen specific immunotherapy and novel ways for vaccine development. Allergology International, 62(4), 425–433.

Kandel, A., Gomaa, M., Nageh, A., Shehata, M. M., Kayed, A. E., Sabir, J. S. M., … Kayali, G. (2019). Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. Viruses, 11, 717. https://doi.org/10.3390/v11080717

Kato, H., Takayama-Ito, M., Izuika-Shiota, I., Fukushima, S., Posadas-Herrera, G., Horiya, M., … Lim, C.-K. (2019). Development of a recombinant replication deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice. PLoS One, 14(10), e0223684. https://doi.org/10.1371/journal.pone.0223684

Kim, H. (2020). Outbreak of novel coronavirus (COVID-19): What is the role of radiologists? European Radiology, 30(6), 3266–3267. https://doi.org/10.1007/s00330-020-06748-2

Kim, Y. C., Dema, B., & Reyes-Sandoval, A. (2020). COVID-19 vaccine: Breaking record times to first-in-human trials. Npj Vaccines, 5(1), 34. https://doi.org/10.1038/s41541-020-0188-3

Kirkchofer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., … Ward, A. B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature, 531, 118–121. https://doi.org/10.1038/nature17200

Klimmek, L., Jutel, M., Ackis, C., Bousquet, J., Ackis, M., Bachert, C., … Zuberbier, T. (2020). Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EEA-ACI statement. Allergy, 75(7), 1546–1554. https://doi.org/10.1111/ALL.14336

Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-L., … Hsueh, P.-R. (2020). Arguments in favor of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 54(5), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933

Koornik, S., Hosseiny, M., Myers, L., & Gholamrezaeezahad, A. (2020). Coronavirus (COVID-19) Outbreak: What the Department of Radiology should know. Journal of the American College of Radiology, 17(4), 447–451. https://doi.org/10.1016/j.jacr.2020.02.008

Kruse, R. L. (2020). Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China, F1000. Philosophy and Phenomenological Research, 9, 72.
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, 55, 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

Lau, S. K. P., Li, K. S. M., Luk, H. K. H., He, Z., Teng, J. L. L., Yuen, K.-Y., Woo, P. C. Y. (2020). Middle East Respiratory Syndrome coronavirus antibodies in bactrian and hybrid camels from Dubai. *mSphere*, 5(1), e00898-19. https://doi.org/10.1128/mSphere.00898-19

Lau, S. K., Woo, P. C., Li, K. S., Huang, Y., Tsai, H. W., Wong, B. H., ... Yuen, K. Y. (2005). Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. *Proceedings of the National Academy of Sciences of USA*, 102, 14040–14045.

Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., ... Pazdur, R. (2018). FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. *The Oncologist*, 23, 943–947. https://doi.org/10.1634/theoncologist.2018-0028

Lee, K. S. (2020). Pneumonia associated with 2019 novel coronavirus: Can computed tomographic findings help predict the prognosis of the disease? *Korean Journal of Radiology*, 21(3), 257–258. https://doi.org/10.3348/kjr.2020.0096

Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., ... Sung, J. J. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. *New England Journal of Medicine*, 348, 1986–1994.

Lei, J., Li, J., Li, X., & Qi, X. (2020). CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. *Radiology*, 295, 18. https://doi.org/10.1148/radiol.2020200236

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., ... Feng, Z. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *New England Journal of Medicine*, 382, 1199–1207. https://doi.org/10.1056/NEJMoa2001316

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., ... Wang, L.-F. (2005). Bats are natural reservoirs of SARS-like coronaviruses. *Science*, 310, 676–679.

Li, X. (2020). Can cats become infected with Covid-19? *Veterinary Record*, 186(14), 457.2–458. https://doi.org/10.1136/vr.m1455

Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., ... Zhang, Z. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nature Medicine*, 26(6), 842–844. https://doi.org/10.1038/s41591-020-0901-9

Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. *Emerging Microbes & Infections*, 9(1), 727–732. https://doi.org/10.1080/222277 751.2020.1746199

Linga, L., Joynt, G. M., Lipman, J., Constantine, J.-M., & Joannes-Boyau, O. (2020). COVID-19: A critical care perspective informed by lessons learnt from other viral epidemics. *Anaesthesia Critical Care & Pain Medicine*, 39(2), 163–166. https://doi.org/10.1016/j. acpcm.2020.02.002

Lipsitch, M., Sverdlov, D. L., & Finelli, L. (2020). Defining the Epidemiology of Covid-19 — Studies Needed. *New England Journal of Medicine*, 382, 1194–1196. https://doi.org/10.1056/NEJMp2002125

Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., ... Albai, D. (2020). Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. *ACS Central Science*, 6, 315–331. https://doi.org/10.1021/acscentsci.0c00272

Liu, J., Cao, R., Xu, M., Wang, X. I., Zhang, H., Hu, H., ... Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery*, 6, 16. https://doi.org/10.1038/s41421-020-0156-0

Liu, J., Zheng, X., Tong, Q., Li, W., Wang, B., Sutter, K., ... Yang, D. (2020). Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *Journal of Medical Virology*, 92(5), 491–494. https://doi.org/10.1002/jmv.25709

Liu, T., Zhang, J., Yang, Y., Zhang, L., Ma, H., Li, Z., ... Yi, J. (2020). The potential role of IL-6 in monitoring coronavirus disease, 2019. *SSRN Electronic Journal*. https://doi.org/10.2139/ssrn.3548761

Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., ... Liu, L. (2020). Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *Journal of Medical Virology*, 92(6), 595–601. https://doi.org/10.1002/jmv.25726

Loczechin, A., Séron, K., Barras, A., Giovanelli, E., Belouzard, S., Chen, Y.-T., & Szunerits, S. (2019). Functional carbon quantum dots as medical countermeasures to human coronavirus. *ACS Applied Materials & Interfaces*, 11, 42964–42974.

Lu, H., Stratton, C. W., & Tang, Y. W. (2020). Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. *Journal of Medical Virology*, 2020(92), 401–402. https://doi.org/10.1002/jmv.25678

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B. O., Wu, H., ... Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet*, 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8

Mahase, E. (2020). China coronavirus: WHO declares international emergency as death toll exceeds 200. *BMJ*, 368, m4080. https://doi.org/10.1136/bmj.m4080

Malainou, C., & Herold, S. (2019). Influenza. *Internist (Berl)*, 60(11), 1127–1135. https://doi.org/10.1007/s00108-019-00670-6

Martina, B. E. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., ... Osterhaus, A. D. M. E. (2003). SARS virus infection of cats and ferrets. *Nature Medicine*, 9(3), 368. https://doi.org/10.1038/425915a

McIntosh, K., Hirsch, M., & Thorner, A. (2017). Middle East respiratory syndrome coronavirus: Virology, pathogenesis, and epidemiology. In T. W. Post (Ed.), *UpToDate*. Waltham, MA: UpToDate Inc.

Menachery, V. D., Schäfer, A., Burnum-Johnson, K. E., Mitchell, H. D., Eisfeld, A. J., Walters, K. B., Boussini, H., ... Eckerle, I. (2015). Serologic assessment of positive coronavirus infections in cats and ferrets. *Nature*, 425, 915. https://doi.org/10.1038/429515a

Menni, C., Sudre, C. H., Steves, C. J., Ourselin, S., & Spector, T. D. (2020). Quantifying additional COVID-19 symptoms will save lives. *The Lancet*, 395(10241), e107–e108. https://doi.org/10.1016/S0140-6736(20)31281-2

Meyer, B., García-Bocanegra, I., Wernery, U., Wernery, U., Wernery, R., Sieberg, A., ... Eckerle, I. (2015). Serologic assessment of positivity for MERS-CoV infection in equids. *Emerging Infectious Diseases*, 21, 181–182.

Miguel, E., Chevalier, V., Ayelet, G., Bencheikh, M. N. B., Boussini, H., Chu, D. K., ... Peiris, M. (2017). Risk factors for MERS coronavirus
infection in dromedary camels in Burkina Faso, Ethiopia, and Morocco. 2015. *Eurosurveillance Weekly*, 22(13), 30498.

Mobaraki, K., & Ahmadzadeh, J. (2019). Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: A cross-sectional study. *BMC Infectious Diseases*, 19, 351.

Momattin, H., Al-All, A. Y., & Al-Tawfiq, J. A. (2019). A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV). *Travel Medicine and Infectious Disease*, 30, 9–18.

Moore, C. A., Staples, J. E., Dobyns, W. B., Pessoa, A., Ventura, C. V., da Fonseca, E. B., … Rasmussen, S. A. (2017). Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. *JAMA Pediatrics*, 171, 288–295.

 Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., … de Wit, E. (2020). Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. *Nature*. https://doi.org/10.1038/s41586-020-2324-7

Nishiura, H., Jung, S.-M., Linton, N. M., Kinoshita, R., Yang, Y., Hayashi, K., … Akhmetzhanov, A. R. (2020). The extent of transmission of novel coronavirus in Wuhan, China, 2020. *Journal of Clinical Medicine*, 9, 330. https://doi.org/10.3390/jcm9020330

Park, M., Thwaites, R. S., & Openshaw, P. J. M. (2020). COVID-19: Lessons from SARS and MERS. *European Journal of Immunology*, 50(3), 308–311. https://doi.org/10.1002/eji.202070035

Patel, A., & Jernigan, D. B. (2020). 2019-nCoV CDC Response Team. 2020. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. *MMWR Morbidity and Mortality Weekly Report*, 69(5), 140–146.

Patri, A., & Fabbrocini, G. (2020). Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and/ or treatment? *Journal of the American Academy of Dermatology*, 82(6), e221. https://doi.org/10.1016/j.jaad.2020.04.017

Perera, R. A., Wang, P., Gomaa, M. R., El-Shesheny, R., Kandeil, A., Bagato, O., Kayali, G. (2013). Seroepidemiology for MERS coronavirus using microneutralisation and pseudotype virus neutralization assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. *Eurosurveillance*, 18(36). https://doi.org/10.2807/1560-7917.es2013.18.36.20574

Perlman, S., & Netland, J. (2009). Coronavirus seroprevalence in the national serological reference population. *Nature Reviews: Microbiology*, 7(6), 439–450.

Phan, L. T., Nguyen, T. V., Luong, Q. C., Nguyen, T. V., Nguyen, H. T., Le, H. Q., … Pham, Q. D. (2020). Importation and human-to-human transmission of a novel Coronavirus in Vietnam. *Revista Panamericana De Salud Publica*, 44, e40. https://doi.org/10.26633/RPSP.2020.40

Ramadan, N., & Shaib, H. (2019). Middle East respiratory syndrome coronavirus (MERS-CoV): A review. *GERMS*, 9(1), 35–42. https://doi.org/10.18683/germs.2019.1155

Rasmussen, S. A., & Hayes, E. B. (2005). Public health approach to emerging infections among pregnant women. *American Journal of Public Health*, 95, 1942–1944.

Rasmussen, S. A., Jamieson, D. J., Honein, M. A., & Petersen, L. R. (2016). Zika virus and birth defects– Reviewing the evidence for causality. *New England Journal of Medicine*, 374, 1981–1987.

Rasmussen, S. A., Smulian, J. C., Ledicky, J. A., Wen, T. S., & Jamieson, D. J. (2020). Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. *American Journal of Obstetrics and Gynecology*, 222(5), 415–426. https://doi.org/10.1016/j.ajog.2020.02.017

Reis, P. E. O., & Lima, M. C. B. (2020). Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? *Journal of Vascular Surgery*, 19, e20200057. https://doi.org/10.1590/1677-5449.200057

Remuzzi, A., & Remuzzi, G. (2020). COVID-19 and Italy: What next? *The Lancet*, 395(10231), 1225–1228. https://doi.org/10.1016/S0140-6736(20)30627-9

Ren, L.-L., Wang, Y.-M., Wu, Z.-Q., Xiang, Z.-C., Guo, L. I., Xu, T., … Wang, J.-W. (2020). Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. *Chinese Medical Journal*, 133, 1015–1024. https://doi.org/10.1097/CMEJ.0000000000000722

Reusken, C., Ababneh, M., Raj, V., Meyer, B., Eljarah, A., Abutarbush, S., … Koopmans, M. (2013). Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. *Eurosurveillance Weekly*, 18(50), 20662. https://doi.org/10.2807/1560-7917.es2013.18.50.20662

Reusken, C. B. E. M., Haagmans, B. L., Müller, M. A., Gutierrez, C., Godeke, G.-J., Meyer, B., … Koopmans, M. P. G. (2013). Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. *The Lancet Infectious Diseases*, 13, 859–866. https://doi.org/10.1016/S1473-3099(13)70164-6

Reusken, C. B. E. M., Schilp, C., Raj, V. S., Bruin, E. D., Kohl, R. H. G., Farag, E. A. B. A., … Koopmans, M. P. G. (2016). MERS-CoV infection of alpaca in a region where MERS-CoV is endemic. *Emerging Infectious Diseases*, 22, 1129–1131.

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechslie, O., Phelan, A., … Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet*, 395, e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4

Roberts, A., Lamirande, E. W., Vogel, L., Jackson, J. P., Paddock, C. D., Aldana, D. K. (2020). Susceptibility of felids to coronaviruses. *Journal of Vascular Surgery*, 76(2), 47–53. https://doi.org/10.1016/j.jvascsurg.2020.01.006

Rodriguez-Morales, A. J., Díaz, K., Chávez-Ramírez, O., Del Río-Andrade, L., Monci, F., … Valdés, M. (2020). SARS-CoV-2 infection in humans and transmission: A systematic review and meta-analysis. *Journal of Travel Medicine*, 27(1), 1–12. https://doi.org/10.1093/jtm/tau016

Rosa, S. G. V., & Santos, W. C. (2020). Clinical trials on drug repositioning for COVID-19 treatment. *Revista Panamericana De Salud Publica*, 44, e40. https://doi.org/10.26633/RPSP.2020.40
Rothana, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, 109, 102433. https://doi.org/10.1016/j.jaut.2020.102433

Sabir, J. S. M., Lam, T.-T.-Y., Ahmed, M. M. M., Li, L., Shen, Y., Abo-Aba, S. E. M., … Guan, Y. (2016). Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science, 351, 81–84.

Schindewolf, C., & Menachery, V. D. (2019). Middle East respiratory syndrome vaccine candidates: Cautious optimism. Viruses, 11(1), 74. https://doi.org/10.3390/v11010074

Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology, 38(1), 10–18.

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98. https://doi.org/10.1016/j.jare.2020.03.005

Shi, H., Han, X., Jiang, N., Cao, Y., Alwailid, O., Gu, J., … Zheng, J. (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. The Lancet Infectious Diseases, 20(4), 425–434. https://doi.org/10.1016/S1473-3099(20)30086-4

Shi, J. Z., Wen, Z. Y., Zhong, G., Yang, H., Wang, C., Liu, R., … Bu, Z. (2020). Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2. BioRxiv. https://doi.org/10.1101/2020.03.03.015347

Shih, H.-I., Wu, C.-J., Tu, Y.-F., & Chi, C.-Y. (2020). Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomedical Journal. https://doi.org/10.1016/j.bj.2020.05.021

Siston, A. M., Rasmussen, S. A., Honein, M. A., Fry, A. M., Seib, K., Callaghan, W. M., … Jamieson, D. J. (2010). Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA, 303, 1517–1525.

Sivabakya, T. K., & Srinivas, G. (2020). Will the antimalarial drug take over to combat COVID-19? Journal of Public Health: from Theory to Practice. https://doi.org/10.15380/s0389-020-01293-0

Snijder, E. J., Bredenbeck, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L., … Gorbalenya, A. E. (2003). Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. Journal of Molecular Biology, 331, 991–1004.

Sohrab, S. S., & Azhar, E. I. (2019). Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia. J. Infect Public Health, 13(5), 709–717. https://doi.org/10.1016/j.jiph.2019.11.007

Suvannarak, N., Kumla, J., Supharit, K., Pattanamanandecha, T., Saenjum, C., & Lumyong, S. (2020). Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses. Molecules, 25, 1800. https://doi.org/10.3390/molecules25081800

Takeayama, K. (2020). In vitro and animal models for SARS-CoV-2 research. Trends in Pharmaceutical Sciences, https://doi.org/10.1016/j.tips.2020.05.005

Teengam, P., Siangphro, W., Tuantranont, A., Vilaivan, T., Chailapakul, O., & Henry, C. S. (2017). Multiplex paper-based colorimetric DNA sensor using pyrroolidinyl peptide nucleic acid-induced AgNPs aggregation for detecting MERS-CoV, MTB, and HPV oligonucleotides. Analytical Chemistry, 89, 5428–5435.

Tetro, J. A. (2020). Is COVID-19 receiving ADE from other coronaviruses? Microbes and Infection, 22, 72–73. https://doi.org/10.1016/j.micinf.2020.02.006

Thorlund, K., Dron, L., Park, J., Hsu, G., Forrest, J. I., & Mills, E. J. (2020). A real-time dashboard of clinical trials for COVID-19. The Lancet: Digital-Health, 2, e286–e287. https://doi.org/10.1016/S2589-7500(20)30086-8

Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., … Zhang, J. (2020). Characteristics of COVID-19 infection in Beijing. Journal of Infection, 80, 401–406. https://doi.org/10.1016/j.jinf.2020.02.018

Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., … Ying, T. (2020). Potent binding of 2019 novel coronavirus spike protein by a SARS-coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections, 9, 382–385. https://doi.org/10.1080/22221751.2020.1729069

Tiwari, R., Dham, K., Sharun, K., Jibal Yatoo, M., Malik, Y. S., Singh, R., … Rodriguez-Morales, A. J. (2020). COVID-19: Animals, veterinary and zoonotic links. Veterinary Quarterly, 40(1), 169–182. https://doi.org/10.1080/01652176.2020.1766725

Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., … Lai, K. N. (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine, 348, 1977–1985.

Tsu, P. T., Kwok, M. L., Yuen, H., & Lai, S. T. (2003). Severe acute respiratory syndrome: Clinical outcome and prognostic correlates. Emerging Infectious Diseases, 9, 1064–1069.

Tu, Y.-F., Chien, C.-S., Yarmishyn, A. A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., … Chiou, S.-H. (2020). A review of SARS-CoV-2 and the ongoing clinical trials. International Journal of Molecular Sciences, 21, 2657. https://doi.org/10.3390/ijms21072657

Tyrell, D. A., & Bynoe, M. L. (1966). Cultivation of viruses from a high proportion of patients with colds. Lancet, 1, 76–77.

USDA (2020). USDA statement on the confirmation of COVID-19 in a tiger in New York. Retrieved from www.aphis.usda.gov/aphis/newsroom/news/sa_by_date/sa-2020/ny-zoo-covid-19

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of Virology, 94(7), e00127-20. https://doi.org/10.1128/JVI.00127-20

Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020). A novel coronavirus outbreak of global health concern. Lancet, 395(10223), 470–473. https://doi.org/10.1016/S0140-6736(20)30185-9

Wang, D., Hu, B. O., Hu, C., Zhu, F., Liu, X., Zhang, J., … Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585

Wang, L., Xu, J., Kong, Y. U., Liang, R., Li, W., Li, J., … Ying, T. (2019). Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies, 8, 53. https://doi.org/10.3390/antib8040053

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., … Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269–271.

Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., … Wang, X. (2013). Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Research, 23(8), 986–993.

Wang, W., Tang, J., & Wei, F. (2020). Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. Emerging Microbes & Infections, 9, 382–385. https://doi.org/10.1080/22221751.2020.1729069
China. Journal of Medical Virology, 92(4), 441–447. https://doi.org/10.1002/jmv.25689
Wang, Y., Kang, H., Liu, X., & Tong, Z. (2020). Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. Journal of Medical Virology, 92, 538–539. https://doi.org/10.1002/jmv.25721
Wei, Q., Wang, Y., Ma, J., Han, J., Jiang, M., Zhao, L., & Liu, J. (2020). Description of the first strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain-National Pathogen Resource Center, China, 2020. Retrieved from http://weekly.chinacdc.cn/en/article/id/c3a460f1-661b-4180-b562-ec9de89502082
Weiss, S. R., & Leibowitz, J. L. (2011). Coronavirus pathogenesis. Advances in Virus Research, 81, Chapter 4, 85–164. Elsevier. https://doi.org/10.1016/B978-0-12-385885-6.00009-2
Wise, J. (2012). Patient with new strain of coronavirus is treated in intensive care at London hospital. BMJ, 345, e6455.
Wong, C. K., Lam, C. W., Wu, A. K., Ip, W. K., Lee, N. L., Chan, I. H., & Wise, J. (2012). Patient with new strain of coronavirus is treated in intensive care at London hospital.
Weiss, S. R., & Leibowitz, J. L. (2011). Coronavirus pathogenesis. Advances in Virus Research, 81, Chapter 4, 85–164. Elsevier. https://doi.org/10.1016/B978-0-12-385885-6.00009-2
World Health Organization (2018). World Health Organization (2018).
World Health Organization. (2020). Coronavirus disease 2019 (COVID-19), Situation Report – 151.
World Health Organization. (2019). World Health Organization. (2019).
World Health Organization (2020). Coronavirus disease 2019 (COVID-19), Situation Report – 151.
World Health Organization (2020a). Novel coronavirus–China. Retrieved from http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
World Health Organization. (2020b). Middle East respiratory syndrome coronavirus (MERS-CoV). Retrieved from https://www.who.int/emergencies/mers-cov/en/
World Health Organization. (2020a). Novel coronavirus–China. Retrieved from http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
World Health Organization. (2020b). Middle East respiratory syndrome coronavirus (MERS-CoV). Retrieved from https://www.who.int/emergencies/mers-cov/en/
World Health Organization. (2020c). Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. Journal of Infection, 80, 388–393. https://doi.org/10.1016/j.jinf.2020.02.016
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., & Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine, 367, 1814–1820.
Zhai, S. L., Wei, W. K., Lv, D. H., Xu, Z.-H., Chen, Q.-L., Sun, M.-F., … Wang, D. (2020). Where did SARS-CoV-2 come from? The Veterinary Record, 186, 254.
Zhai, S.-L., Wei, W.-K., Lv, D.-H., Zhai, Q. I., Wen, X.-H., Xu, Z.-H., … Chen, Q.-L. (2020). Can cats become infected with Covid-19? Veterinary Record, 186(17), e20. https://doi.org/10.1136/vr.m1581
Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., … Hilgenfeld, R. (2020). α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. Journal of Medicinal Chemistry, 63(9), 4562–4578. https://doi.org/10.1021/acs.jmedchem.9b01828
Zhang, Q., Wang, Y., Qi, C., Shen, L., & Li, J. (2020). Clinical trial analysis of 2019-nCoV therapy registered in China. Journal of Medical Virology, 92, 540–545. https://doi.org/10.1002/jmv.25733
Zhang, Q., Zhang, H. J., Huang, K., Yang, Y., Hui, X., Gao, J., … Jin, M. (2020). SARS-CoV-2 neutralizing serum antibodies in cats: A serological investigation. BioRxiv. https://doi.org/10.1101/2020.04.01.021196
Zhang, S., Diao, M. Y., Yu, W., Pei, L., Lin, Z., & Chen, D. (2020). Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis. International Journal of Infectious Diseases, 93, 201–204. https://doi.org/10.1016/j.ijid.2020.02.033
Zhang, T., Wu, Q., & Zhang, Z. (2020). Pangolin homology associated with 2019-nCoV. bioRxiv. https://doi.org/10.1101/2020.02.19.950253
Zhong, J., Tang, J., Ye, C., & Dong, L. (2020). The immunology of COVID-19: Is immune modulation an option for treatment? The Lancet Rheumatology, 2(7), e428–e436. https://doi.org/10.1016/S2665-9913(20)30120-X
Zhou, L., Zhang, M., Wang, J., & Gao, J. (2020). Sars-Cov-2: Underestimated damage to nervous system. Travel Medicine and Infectious Disease, 101642. https://doi.org/10.1016/j.tmaid.2020.101642
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., … Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270–273. https://doi.org/10.1038/s41586-020-2008-3
Wu, P., Hao, X., Lau, E. H. Y., Wong, J. Y., Leung, K. S. M., Wu, J. T., … Leung, G. M. (2020). Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance Weekly, 25(3), 2000044. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000044
Xu, C., Wang, J., Yang, J., Chen, P., Feng, J., Zhou, H., Li, X., … Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences, 63, 457–460. https://doi.org/10.1007/s11427-020-1637-5
Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., Zhu, W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv, 2027, 921627. https://doi.org/10.1101/2020.01.27.921627
Yang, W., Cao, Q., Qin, L. E., Wang, X., Cheng, Z., Pan, A., … Yan, F. (2020). Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. Journal of Infection, 80, 388–393. https://doi.org/10.1016/j.jinf.2020.02.016
in China, 2019. *New England Journal of Medicine*, 382, 727–733. https://doi.org/10.1056/NEJMoa2001017

Zhu, Z., Dimitrov, A. S., Bossart, K. N., Crameri, G., Bishop, K. A., Choudhry, V., … Dimitrov, D. S. (2006). Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. *Journal of Virology*, 80, 891–899. https://doi.org/10.1128/JVI.80.2.891-899.2006

Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016). Coronaviruses-drug discovery and therapeutic options. *Nature Reviews: Drug Discovery*, 15, 327–347. https://doi.org/10.1038/nrd.2015.37

How to cite this article: Mohapatra RK, Pintilie L, Kandi V, et al. The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. *Chem Biol Drug Des*. 2020;96:1187–1208. https://doi.org/10.1111/cbdd.13761